8:20 am Chair’s Opening Remarks

The Third Access: Successfully Inducing Tolerance

8:30 am Checkpoint Inhibitors: Insights into Immune Tolerance

  • Jack Ragheb Senior Medical Fellow for Immunology in Global Patient Safety, Eli Lilly & Co.

9:00 am Exploring the Parameters by which Tolerance Induction is Determined

9:30 am Immune Tolerance Induction via Allogeneic Exosomes

  • Giles Benichou Associate Professor of Surgery, Harvard Medical School, Senior Immunologist, Massachusetts General Hospital

10:00 am Morning Break & Refreshments

10:30 am T Cell Anergy Induction by Pharmacological Agents Partially Restricting T Cell Activation

  • Garth Ringheim Director Immunology Therapeutic Area, Clarivate Analysis

11:00 am Establish Tolerance in MS with Myelin-Peptide Coupled Red Blood Cells

11:30 am Activation of the Aryl Hydrocarbon Receptor by Antigen-Specific Tolerogenic Nanoparticles for the Treatment of Autoimmune Diseases

12:00 pm Lunch & Networking

Tolerance Induction in Parallel Fields: What Lessons can be Applied for Autoimmune Diseases

1:00 pm Antigen Specific Tolerance in Autoimmunity & in Gene Therapy

  • Lawrence Steinman Professor of Neurology, Neurological Sciences & Pediatrics, Stanford University

1:30 pm Antigen-Specific T & B Cell Profiles as Therapeutic Targets in Allergy & Autoimmune Disease

2:00 pm Unraveling the Mechanism of Desensitization & Tolerance through Food Allergen-Specific Oral Immunotherapy

  • Monali Manohar Life Science Research Scientist, Stanford University School of Medicine

What Assays do we use & when? Developing Assays for Clinical Trials

2:30 pm FlowSpot: A Single Platform Assay with Broad Versatility for Measuring Cellular & Humoral Immune Status, Responsiveness & Memory

  • Dolly Tyan Professor; Emerita of Pathology, Stanford University School of Medicine

3:00 pm Assay Development for AKS-107, an Insulin-Fc Biologic Designed to Target Insulin-Specific B Cells in Type 1 Diabetes (T1D)

3:30 pm Afternoon Refreshments & Networking

4:00 pm Panel Discussion: “Bridging the Valley of Death: Non-Profit Organizations as Enablers of Novel Commercial T1D Therapeutics from Research to Phase II”

  • David Alleva Executive Director, Akston Biosciences
  • Todd Zion President & Chief Executive Officer, Akston Biosciences
  • Ben Williams Program Officer for the Type 1 Diabetes (T1D) Program, Helmsley Charitable Trust
  • Kurt Griffin Associate Professor , University of South Dakota Sanford School of Medicine

Exploring Clinical Opportunities to use Combination Strategies to Successfully Deliver Tolerance Inducing Therapeutics

4:30 pm Considerations for Dual Therapy Approaches in Autoimmune Disease

  • Joshua Sestak President and Chief Executive Officer, Founder, Orion BioScience

5:00 pm Novel Applications of Localized Delivery of Combination Strategies for Modulation of Allo- & Auto-Reactivity

  • Giorgio Raimondi Associate Scientific Director for Transplant Immunology, John Hopkins School of Medicine

5:30 pm Chair’s Closing Remarks